We have established a track record of efficient and consistent achievement.
HARMONY Phase 2b Study Readout
Our topline Ph 2b data achieved statistical significance on both primary and secondary histology endpoints after 24 weeks in patients with pre-cirrhotic NASH (F2-F3).
Upsized Public Follow-On Offering
Following topline HARMONY data, we closed an upsized underwritten public offering with gross proceeds of approximately $230M.
Breakthrough Therapy Designation
Lead candidate EFX was granted Breakthrough Therapy Designation from the US FDA for the treatment of NASH.
BALANCED Expansion Cohort Readout
We reported early evidence that EFX has the potential to reverse fibrosis for cirrhotic NASH patients.
Phase 2b HARMONY and SYMMETRY Study Initiation
Parallel studies in pre-cirrhotic and cirrhotic NASH are the next step toward a potential commercialization of EFX, if approved.
Phase 2a BALANCED Study Readouts
Our topline liver fat, liver injury, metabolic and biopsy data showed strongly positive and consistent improvements across multiple parameters for NASH.
$216M Upsized Follow-On Offering
Our cumulative financing surpassed $400M with an upsized follow-on offering at the top of the marketing range.
New Corporate Headquarters
We completed renovation of our new corporate headquarters in South San Francisco, CA.
$45M Series A Financing and Amgen License
We entered an exclusive, global license from Amgen to develop EFX, backed by blue-chip investors.
$45.5M Series B Financing
Our crossover financing with a dozen top-tier private investors paved the way for a successful IPO.
We partnered with Boehringer-Ingelheim and Vetter Pharma to ensure high quality API and drug product.